为您找到"
ANX-09
"相关结果约100,000,000个
ANX009 Dose 2 ANX 009 Dose 4 A. Single ascending dose B. Multiple acsending dose Placebo ANX009 Cohort 1 (daily dosing) ANX C oh rt 2 (t w ice eekly d s ng) • Ex vivo functional activity of C1q in serum, as measured by CH 50 in sensitized red blood cell hemolysis assays, was inhibited in close correspondence with free C1q levels Pharmacokinetics
Certain autoantibodies that bind to tissue antigens or that deposit in tissues as a component of immune complexes can activate the classical complement cascade, leading to inflammation and tissue damage.
News for ANX009 / Annexon Biosci. Results of Single-Arm, Phase 1b Study of Anti-C1q Treatment (ANX009) Show That the Classical Pathway Is a Key Driver of Complement Activation and Consumption in Patients with Active Lupus Nephritis (ACR Convergence 2023) - "In this interim analysis, ANX009 administered subcutaneously was well tolerated and demonstrated C1q target engagement and complement ...
All participants may continue to receive stable background standard of care therapy for LN and systemic lupus erythematosus (SLE) as permitted by the protocol (for example, mycophenolate mofetil [MMF], azathioprine, antimalarials, glucocorticoids, cyclosporin, voclosporin, tacrolimus, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs]).
The C1q inhibitor ANX009 was found to be safe, tolerable, and have favorable pharmacology in a phase 1 clinical trial with healthy individuals, supporting its advancement into testing its efficacy in patients with complement-mediated autoimmune disorders such as cold agglutinin disease (CAD).. These trial results were presented as a poster at the 63rd American Society of Hematology (ASH ...
All participants may continue to receive stable background standard of care therapy for LN and systemic lupus erythematosus (SLE) as permitted by the protocol (for example, mycophenolate mofetil [MMF], azathioprine, antimalarials, glucocorticoids, cyclosporin, voclosporin, tacrolimus, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs]).
ARCHER Trial Results Presented at ASRS Further Demonstrate Preservation of Visual Function in Patients with Geographic Atrophy; Company to Engage Regulatory Agencies to Determine Optimal Path Forward Multiple Key Catalysts Expected in Second Half 2023, Including Completion of Enrollment in the Phase 3 Pivotal Trial of ANX005 in GBS and Phase 1 Data from ANX1502 Oral Small Molecule Company to ...
ANX-009 Alternative Names: anx-009, anx 009, anx009 Latest Update: 2024-08-22 Latest Update Note: Clinical Trial Update
A Single-Arm, Phase 1b, Open-Label Study to Assess the Safety, Tolerability, and Pharmacodynamics of Repeat-Doses of Subcutaneous ANX009 With Standard of Care Therapy in Adult Participants With Lupus Nephritis
ANX 009 Alternative Names: ANX-009 Latest Information Update: 28 Dec 2023 Price : $50 * Buy Profile. Note: Adis is an information provider. We do not sell or distribute actual drugs. Final gross price and currency may vary according to local VAT and billing address. ...